| Article | Added |
|---|
| St. Jude Medical EnligHTNment Study Highlighted at EuroPCR During Trials That May Change Clinical Practice Session | 05-21-13 |
| EnligHTNment-Studie von St. Jude Medical auf dem EuroPCR-Kongress in der Sitzung ?Trials That May Change Clinical Practice? hervorgehoben | 05-21-13 |
| Samenvatting: Biogen Idec vraagt goedkeuring aan bij FDA voor PLEGRIDY (Peginterferon Beta-1a) bij multiple sclerosis | 05-21-13 |
| Biogen Idec Submits Application to FDA for Approval of PLEGRIDY? (Peginterferon Beta-1a) in Multiple Sclerosis | 05-21-13 |
| Biogen Idec presenta all'FDA una domanda di approvazione per il PLEGRIDY? (Peginterferone Beta-1a) per la sclerosi multipla | 05-21-13 |
| Biogen Idec soumet une demande auprès de la FDA pour l'approbation du PLEGRIDY? (peginterféron bêta-1a) contre la sclérose en plaques | 05-21-13 |
| Biogen Idec reicht Zulassungsantrag für PLEGRIDY? (Peginterferon Beta-1a) zur Behandlung der multiplen Sklerose bei der FDA ein | 05-21-13 |
| Biogen Idec presenta solicitud ante la FDA para aprobación de PLEGRIDY? (Peginterferón Beta-1a) sobre esclerosis múltiple | 05-21-13 |
| Impax Board of Directors Establishes Compliance Committee | 05-20-13 |
| STENTYS Enrolls First Heart Attack Patient in Pivotal U.S. Clinical Trial | 05-20-13 |
| Acurian Announces Partnership Agreement with the Society for Clinical Research Sites (SCRS) | 05-20-13 |
| CytRx Issues Letter to Stockholders Providing Business Update | 05-20-13 |
| Covidien Receives FDA 510(k) Clearance for Nellcor? Pulse Oximetry Motion Claims | 05-20-13 |
| Synageva's Sebelipase Alfa Receives Breakthrough Therapy Designation for Early Onset LAL Deficiency from the U.S. Food and Drug Administration | 05-20-13 |
| R-Tech Ueno: Start of the Patient Enrollment of a Phase I/II Clinical Study of Recombinant Human Serum Albumin-Containing Ophthalmic Solution (Development Code: RU-101) in US for the Treatment of Severe Dry Eye | 05-20-13 |
| Cytori Reports First Quarter 2013 Business and Financial Results | 05-09-13 |
| SARTA MedStart Progress Report Identifies 18 New Med Tech Companies | 05-09-13 |
| CA Technologies Declares Quarterly Dividend | 05-09-13 |
| NEC Display Solutions Receives FDA 510(k) Clearance on MD211C2 and MD211C3 Medical Diagnostic Monitors | 05-09-13 |
| BioCryst to Present at Two Upcoming Investor Conferences | 05-09-13 |
| ISR's Risk-based Monitoring Report Offers Industry Peer-based Guidance | 05-09-13 |
| ACRO Launching New Video Series With Health Coalition Leaders | 05-09-13 |
| Kips Bay Medical Provides FDA Update and Reports First Quarter 2013 Results | 05-09-13 |
| GAO Dismisses Request for Reconsideration by ERBE Contractor, Supporting Previous Ruling in Favor of Bidder Offering US Medical Innovations, LLC's Product | 05-08-13 |
| Healthx Wireless Monitoring for High-Risk Patients Reduces Costly ER Visits and Readmissions | 05-08-13 |
| Merck Announces FDA Acceptance of Biologics License Application for Investigational Ragweed Pollen Sublingual Allergy Immunotherapy Tablet | 05-08-13 |
| Antares Pharma Reports First Quarter 2013 Operating and Financial Results | 05-08-13 |
| Navidea Biopharmaceuticals Announces First Quarter 2013 Results | 05-08-13 |
| Elixir Medical Announces FDA Approval to Commence EXCELLA III Clinical Trial with DESyne® Nx Novolimus Eluting Coronary Stent System in the United States | 05-08-13 |
| USDA Supports Continued Use of Carrageenan for Organic Foods | 05-08-13 |
| First Databank Research on Use of Structured Product Labeling to Identify Prescription Drugs With Boxed Warnings Finds Numerous Inconsistencies | 05-08-13 |
| Toshiba Infinix-i System Displays Radiation Dose Exposure to Improve Patient Safety | 05-08-13 |
| Furiex Reports First Quarter 2013 Financial Results | 05-07-13 |
| Boston Physician Awarded Master of the American College of Endocrinology | 05-07-13 |
| Inolex Publishes White Paper on the Excellent Health and Safety Profile of Synthetic Esters | 05-07-13 |
| Life Spine® Announces FDA Clearance of IRIS? Anterior Cervical Plate (ACP) System | 05-07-13 |
| Arizona Physician Presented with a Distinguished Award from Major Medical Association | 05-07-13 |
| United States Senator Presented Public Service Award by National Medical Association | 05-07-13 |
| New Hampshire Physician Presented Endocrine Teaching Award | 05-07-13 |
| FDA Approves BIOTRONIK's Ilesto 7 ICD/CRT-D Series | 05-07-13 |
| Enrollment Completed for Low-Risk Aortic and Mitral Patient Groups For On-X® Prosthetic Heart Valve Anticoagulation Clinical Study | 05-07-13 |
| FDA Grants Fast Track Designation for Cubist's Late-Stage Antibiotic Candidate | 05-07-13 |
| X-spine Announces FDA Clearance of New Spinal Implant System | 05-07-13 |
| San Diego Physician Installed as President of the American College of Endocrinology | 05-06-13 |
| Dallas Based Physician Elected Secretary of Major Physician Organization | 05-06-13 |
| Illinois Based Physician Elected Treasurer of Major Physician Organization | 05-06-13 |
| Florida Physician Becomes President Elect of Major Physician Organization | 05-06-13 |
| Triumph Over Superbugs Will Only Come from C-Suite-Supported Multimodal Intervention, Says Environmental Hygiene Advocate | 05-06-13 |
| Breakthrough Therapy Designation from the U.S. Food and Drug Administration Granted to Investigational HCV Regimen Containing Protease Inhibitor ABT-450 | 05-06-13 |
| Sub-Group Analysis Shows Investigational Metreleptin Treatment Demonstrated Reductions in HbA1c, Triglycerides and Liver Function Tests in Pediatric Patients with Lipodystrophy During a 12-Month Period | 05-06-13 |
| Using Sweat to Detect Diabetic Neuropathy | 05-03-13 |
| Study Underscores Importance of Physical Exams As Diagnostic Tool for Thyroid Cancer | 05-03-13 |
| Cause and Effect: Case Report Shows an Association between Sugar Substitutes and Common Thyroid Disorder | 05-03-13 |
| FDA Approves Merck's LIPTRUZET? (ezetimibe and atorvastatin), a New Product That Can Help Powerfully Lower LDL Cholesterol | 05-03-13 |
| Navidea Biopharmaceuticals to Announce First Quarter 2013 Financial Results Pre-market on Wednesday, May 8, 2013 | 05-03-13 |
| St. Jude Medical to Present at the Bank of America Merrill Lynch 2013 Health Care Conference | 05-03-13 |
| Bristol-Myers Squibb Receives US FDA sNDA Approval for Use of SUSTIVA® (efavirenz) in HIV-1 Infected Pediatric Patients | 05-03-13 |
| Santarus to Present at May and June Investment Conferences | 05-03-13 |
| When Fat Is Good: Brown Adipose Tissue (BAT) Shows Potential As Obesity Buster | 05-02-13 |
| FDA Advisory Committee Unanimously Recommends JUVÉDERM VOLUMA? XC as a Safe and Effective Treatment Option for Cheek Augmentation to Correct Age-Related Volume Deficit in the Mid-Face | 05-02-13 |
| AtriCure Reports First Quarter 2013 Financial Results | 05-02-13 |
| Robotic Angioplasty Achieves 97.6 Percent Clinical Success Rate | 05-02-13 |
| Kips Bay Medical Announces the First eSVS® Mesh Implant by the Mayo Clinic | 05-02-13 |
| Aspen Technology to Host Investor Day | 05-02-13 |
| Trading of AVEO Common Stock Halted | 05-02-13 |
| Roetzel Welcomes Food and Drug Attorneys Edgar Asebey-Birkholm and James T. O?Reilly | 05-01-13 |
| Navidea Biopharmaceuticals Announces the U.S. Launch of Lymphoseek® | 05-01-13 |
| FDA Approves Over-The-Counter Availability of Plan B One-Step® (levonorgestrel) tablet 1.5 mg for Consumers 15 and Over | 04-30-13 |
| FDA Approves ACTEMRA® for Children Living with a Rare Form of Arthritis | 04-30-13 |
| Ballantyne Brands Joins The We Card® Manufacturers Advisory Council | 04-30-13 |
| Gilead recibe cartas de respuesta completas de la Agencia de Alimentos y Fármacos (FDA) de Estados Unidos para elvitegravir y cobicistat | 04-30-13 |
| Teleflex Reports First Quarter 2013 Results | 04-30-13 |
| ReVision Optics Raindrop Near Vision Inlay Featured in Presentations at the 2013 ASCRS Symposium | 04-30-13 |
| ETView Medical, Ltd. Announces US FDA Clearance of a 510(k) Pre-marketing Notification Application Expanding the VivaSight?-DL line of Innovative Airway Devices | 04-30-13 |
| Gilead heeft Complete Response Letters ontvangen van de Amerikaanse Food And Drug Administration voor elvitegravir en cobicistat | 04-29-13 |
| Michael Fitzpatrick Joins Personalis as Vice President Worldwide Sales | 04-29-13 |
| Gilead reçoit des lettres de réponse complète de l?organisme américain de surveillance des aliments et des médicaments (U.S. Food and Drug Administration) pour l'elvitégravir et le cobicistat | 04-29-13 |
| Gilead riceve dalla Food & Drug Administration (FDA) statunitense le lettere di responso completo per elvitegravir e cobicistat | 04-29-13 |
| FDA Accepts Octapharma USA Biological License Application for octaplex® ? an Investigational 4-Factor PCC | 04-29-13 |
| Sorin Group Announces Results for the First Quarter of 2013 | 04-29-13 |
| Sorin Group Annuncia I Risultati Del Primo Trimestre 2013 | 04-29-13 |
| Sorin Group Receives Conditional FDA Approval to Conduct IDE Clinical Trial for Perceval (TM) S Sutureless Aortic Valve in the United States | 04-29-13 |
| SORIN GROUP OTTIENE L?APPROVAZIONEFDA PER CONDURRE NEGLI STATI UNITI LO STUDIO CLINICO IDE DELLA VALVOLA AORTICA SUTURELESS PERCEVA (TM) S | 04-29-13 |
| Gilead erhält umfassende Antwortschreiben von FDA in Bezug auf Elvitegravir und Cobicistat | 04-29-13 |
| Blockade MedicalTM Announces 510(k) Clearance of the Barricade Coil System and Completion of the First Series of Clinical Cases | 04-29-13 |
| Gilead Receives Complete Response Letters from U.S. Food and Drug Administration for Elvitegravir and Cobicistat | 04-29-13 |
| Teleflex Receives FDA 510(k) Clearance for Next Generation Vascular Positioning System® | 04-29-13 |
| Hi-Tech Pharmacal to Present at the Needham 12th Annual Healthcare Conference | 04-29-13 |
| InVivo Therapeutics? CEO Scheduled to Appear on FOX Business Network's ?Varney & Company? | 04-29-13 |
| NinePoint Medical Receives Additional FDA 510(k) Clearance for NvisionVLE Imaging System | 04-26-13 |
| InVivo Therapeutics? CEO Scheduled to Appear on Business News Network's ?The Close? in Canada | 04-26-13 |
| R-Tech Ueno Receives FDA IND Approval for RU-101 (r-HSA) to Treat Severe Dry Eye | 04-26-13 |
| Innovations in Neuromodulation | 04-26-13 |
| IGI Laboratories Announces 1st Quarter 2013 Results | 04-25-13 |
| Navidea Biopharmaceuticals to Present at the Needham 12th Annual Healthcare Conference | 04-25-13 |
| Medgenics Reports Positive Interim Results from Ongoing Phase IIa Study of EPODURE to Treat Anemia in Dialysis Patients | 04-25-13 |
| The StabiLink? MIS Spinal Fixation System Offers New Minimally Invasive Option for Spine Surgeons | 04-25-13 |
| Ipsen expects Increlex® supply interruption due to supplier manufacturing issues | 04-25-13 |
| Ipsen prévoit une rupture de l?approvisionnement d?Increlex® suite aux problèmes de fabrication de son fournisseur | 04-25-13 |
| Once-daily AUBAGIO® Delayed Onset of Clinically Definite Multiple Sclerosis (MS) in TOPIC Study | 04-25-13 |
| Fibrocell Science Pursues Premium Aesthetic Market Position for LAVIV® | 04-24-13 |
| Paragon Solutions Releases NextDocs Migration Solution for Life Sciences | 04-24-13 |
| Defibtech Receives 2013 ?Exporter of the Year? Award from ThinkGlobal Inc., publisher of U.S. Department of Commerce Magazine | 04-24-13 |
| Cerus Announces FDA Agreement on Modular Premarket Approval (PMA) Application Submission Process for INTERCEPT Platelets | 04-24-13 |
| Metabolon Expands Biochemical Profiling Capabilities with the New TrueVision? Metabolomics Offering and Online Client Tools | 04-23-13 |
| Traceability in QAD Enterprise Applications Helps Deliver Peace of Mind for Food and Beverage Manufacturers | 04-23-13 |
| CytRx Announces Agreement with FDA on Special Protocol Assessment for Global Pivotal Phase 3 Clinical Trial with Aldoxorubicin for Soft Tissue Sarcoma | 04-23-13 |
| Teva and Xenon Announce FDA Orphan Drug Designation for Pain Drug XEN402 | 04-23-13 |
| Forest Laboratories, Inc. Reports Fiscal Year Fourth Quarter 2013 Earnings Per Share of $0.17 Including $0.08 Per Share of Acquisition Amortization | 04-23-13 |
| FDA Approves Supplemental New Drug Application for AMITIZA® (lubiprostone), the First Oral Treatment for Opioid-induced Constipation in Adults with Chronic Non-Cancer Pain | 04-23-13 |
| ImageIQ and IMARC Research Announce Innovative Co-Marketing Partnership | 04-23-13 |
| Alliance for Food and Farming: Read Actual USDA Pesticide Report, Not Re-Interpretation | 04-22-13 |
| Medgenics Receives Notice of Allowance from the U.S. Patent Office for Claims That Expand IP for Its Platform Technology to Additional Therapeutic Proteins | 04-22-13 |
| Synta Announces First Patients Treated in Pivotal GALAXY-2 Trial Evaluating Ganetespib in Advanced Non-Small Cell Lung Cancer | 04-22-13 |
| American Association of Clinical Endocrinologists Releases Comprehensive Diabetes Management Algorithm for Treatment of Diabetes and Prediabetes Patients | 04-19-13 |
| Madonna ICARE by SportsArt Earns International da Vinci Innovation Award | 04-19-13 |
| Navidea Biopharmaceuticals Announces that Results of NAV4694 Clinical Trial Published in the Journal of Nuclear Medicine | 04-18-13 |
| FDA Clears Microline Surgical Flexible Ligating Shears for Advanced Tissue Sealing | 04-18-13 |
| Genzyme Convenes 13th European Fabry Disease Roundtable | 04-18-13 |
| Top-Line Data Show Exact Sciences? Cologuard Test Demonstrates 92 Percent Sensitivity in the Detection of Colorectal Cancer | 04-18-13 |
| Elorac, Inc. Announces FDA Fast Track Designation for Novel Topical Treatment for Pruritus in Cutaneous T-cell Lymphoma (CTCL) | 04-12-13 |
| Otsuka's New Drug Application for Tolvaptan, the Investigational Compound for Autosomal Dominant Polycystic Kidney Disease (ADPKD), Accepted for Review by the US Food and Drug Administration (FDA) | 04-12-13 |
| ???????????????? ?????????????ADPKD??????????? ??FDA?????NDA??? | 04-12-13 |
| Navidea's Presentation of Top-Line Interim Analysis of Lymphoseek® Head and Neck Phase 3 Trial Selected for Investigator Award | 04-11-13 |
| Teleflex Receives FDA 510(k) Clearance for the ISO-Gard® Mask with ClearAir? Technology | 04-11-13 |
| CorMedix Notified of NYSE MKT Listing Deficiency | 04-11-13 |
| Internationally Acclaimed Innovator Daniel Kraft to Give Keynote Address at DIA 2013 49th Annual Meeting | 04-11-13 |
| First Clinical Study Demonstrates Vent-Os? Sinus Dilation System Effectively Establishes and Maintains Patency of Maxillary Sinus Ostia | 04-11-13 |
| Amarantus Announces Preclinical Development Timeline for MANF Therapeutic | 04-11-13 |
| ACADIA Pharmaceuticals Announces Expedited Path to NDA Filing for Pimavanserin Following Meeting with FDA | 04-11-13 |
| FDA Review Periods are Lengthening for Biomarker-Based IVD Tests, Announces Amplion Research | 04-10-13 |
| Provectus Presents Data on PV-10 Combination Therapy at American Association of Cancer Research Annual Meeting | 04-10-13 |
| MED-EL Launches World's First Single-Unit Processor for Cochlear Implants | 04-10-13 |
| Research and Markets: FDA Approval Process for Medical Devices - Updated Programme (Seminar, London) | 04-10-13 |
| BioLineRx Receives Regulatory Approval to Commence Phase II Clinical Trial for BL-8040, for Treatment of Leukemia | 04-10-13 |
| Innovations in Neuromodulation | 04-10-13 |
| Furiex Pharmaceuticals Announces First Quarter 2013 Earnings Release and Conference Call | 04-09-13 |
| FDA Clears the Terumo BCT Trima Accel® Automated Blood Collection System for the Collection and Storage of Platelets in PAS | 04-09-13 |
| Gilead dépose auprès de la FDA américaine une demande d'homologation du sofosbuvir pour le traitement de l'hépatite C | 04-09-13 |
| Gilead presenta solicitud de nuevo fármaco ante la FDA de Estados Unidos de sofosbuvir para el tratamiento de la hepatitis C | 04-09-13 |
| Gilead reicht neue Anwendung für Sofosbuvir zur Behandlung von Hepatitis C bei der US-amerikanischen Arzneimittelbehörde ein | 04-09-13 |
| Gilead deposita una domanda di approvazione di nuovo farmaco (New Drug Application, NDA) presso l'Agenzia per gli Alimenti e i Medicinali statunitense (Food and Drug Administration, FDA) per sofosbuvir per il trattamento dell'epatite C | 04-09-13 |
| Gilead dient New Drug Application in bij de Amerikaanse FDA voor sofosbuvir voor de behandeling van hepatitis C | 04-09-13 |
| Gilead Submits New Drug Application to U.S. FDA for Sofosbuvir for the Treatment of Hepatitis C | 04-08-13 |
| AUBAGIO® (teriflunomida) oral para administração uma vez por dia aprovado na Argentina para o tratamento de esclerose múltipla reincidente | 04-08-13 |
| AUBAGIO® (teriflunomida) una vez al día por vía oral, de Genzyme, autorizado en Argentina para el tratamiento de la esclerosis múltiple recurrente | 04-08-13 |
| Genzyme's Once-daily, Oral AUBAGIO® (teriflunomide) Approved in Argentina for the Treatment of Relapsing Multiple Sclerosis | 04-08-13 |
| Amarantus Outlines LymPro Alzheimer's Diagnostic Development Strategy | 04-08-13 |
| Best Medical International and its family of companies, collectively known as TeamBest, are growing by acquiring and expanding organically | 04-08-13 |
| ERYTECH Pharma??????????????????????????FDA??IND????? | 04-05-13 |
| InVivo Therapeutics Receives Approval from FDA for First Human Trial Using Biomaterials for Traumatic Spinal Cord Injury | 04-05-13 |
| Furiex Pharmaceuticals to Receive Milestone Payment for Priligy® Launch in France | 04-04-13 |
| GE and StartUp Health Select 13 Consumer Health Companies for Entrepreneurship Program | 04-04-13 |
| pSivida Announces Tech Evaluation Agreement With Leading Global Pharmaceutical Company | 04-04-13 |
| InVivo Therapeutics Receives Humanitarian Use Device Designation for Spinal Cord Injury Treatment | 04-04-13 |
| Dr. Reddy's Announces the Launch of Zoledronic Acid Injection | 04-04-13 |
| ERYTECH Pharma erhält IND-Zulassung der FDA zur Einleitung einer klinischen Studie zu akuter lymphoblastischer Leukämie in den USA | 04-04-13 |
| Thermo Fisher Scientific Test Method Detects Dangerous Phenylbutazone in Horsemeat | 04-03-13 |
| Actium Biosystems Establishes Scientific Advisory Board (SAB) in Anticipation of an Application to the FDA to Conduct a Phase I First-in-Human Clinical Study of Its Thermal Nanomedicine Cancer Treatment | 04-03-13 |
| Riassunto: ERYTECH Pharma riceve l'autorizzazione all'IND da parte dell'FDA per dare il via a uno studio clinico sulla leucemia linfoblastica acuta negli USA | 04-03-13 |
| ISR Report Provides Medical Device Industry with Analysis of Historical Trials, Development Market Size, and Manufacturer Profiles | 04-03-13 |
| Samenvatting: ERYTECH Pharma krijgt toestemming voor studie 'Acute Lymphoblastic Leukemia' in V.S. | 04-03-13 |
| Resumen: ERYTECH Pharma recibe aprobación FDA IND para iniciar un estudio clínico sobre leucemia linfoblástica aguda en Estados Unidos | 04-03-13 |
| Hitachi Medical Systems America Announces FDA Clearance of Its SCENARIA? Advanced 128-Slice CT System | 04-03-13 |
| Samenvatting: Biogen Idec rondt aankoop af TYSABRI-rechten | 04-03-13 |
| New Therapy for the Management of HIV-associated Enteropathy from Entera Health | 04-03-13 |
| ERYTECH Pharma reçoit le feu vert de la FDA pour initier une étude clinique dans la Leucémie Aiguë Lymphoblastique aux Etats-Unis | 04-03-13 |
| ERYTECH Pharma Receives FDA IND Clearance to Initiate a Clinical Study in Acute Lymphoblastic Leukemia in the U.S. | 04-03-13 |
| Biogen Idec completa la adquisición de todos los derechos y control de TYSABRI® | 04-03-13 |
| LENSAR Laser System? Receives FDA Clearance for Arcuate Incisions in Cataract Surgery | 04-03-13 |
| Biogen Idec erwirbt umfassende Rechte an TYSABRI® | 04-03-13 |
| Biogen Idec completa l'acquisto di tutti i diritti e ottiene il pieno controllo di TYSABRI® | 04-03-13 |
| Biogen Idec finalise l?achat de l?intégralité des droits et du contrôle de TYSABRI® | 04-02-13 |
| Biogen Idec Completes Purchase of Full Rights and Control of TYSABRI® | 04-02-13 |
| Terra Tech Corp. Taps Former Executive Director of the FDA for Advisory Board | 04-02-13 |
| AxioMed® Spine Corporation Receives Pivotal Total Disc Design Patent | 04-02-13 |
| Bingham Memorial Hospital to be First to Offer Reflux Procedure in Intermountain West | 04-01-13 |
| pSivida Reports on Resubmission to FDA of NDA for ILUVIEN® for Chronic Diabetic Macular Edema | 04-01-13 |
| BioCryst Pharmaceuticals Provides Update Regarding Peramivir | 04-01-13 |
| FDA Approves New Drug Application (NDA) for Teva's Quartette? (levonorgestrel/ethinyl estradiol and ethinyl estradiol) Tablets for the Prevention of Pregnancy | 03-29-13 |
| Dipotassium Glycyrrhizinate (CAS 68797-35-3) Market Studied in Discounted BAC Report Now Available at MarketPublishers.com | 03-29-13 |
| Dr. Reddy's Announces the Launch of Zenatane? (Isotretinoin Capsules USP) | 03-29-13 |
| Kips Bay Medical Provides FDA Update & Reports Fourth Quarter and Full Year 2012 Results | 03-28-13 |
| BDC Laboratories Announces VDT-3600i Heart Valve Accelerated Wear Test System | 03-28-13 |
| Vetter's Newest Facility Successfully Completes FDA Inspection | 03-28-13 |
| A.P. Pharma Receives FDA Complete Response Letter for APF530 | 03-28-13 |
| Pfizer's BOSULIF® (bosutinib) Receives Conditional Marketing Authorization From The European Commission | 03-28-13 |
| CorMedix Reports Year End 2012 Financial Results | 03-27-13 |
| Biogen Idec's TECFIDERA? (Dimethyl Fumarate) Approved in US as a First-Line Oral Treatment for Multiple Sclerosis | 03-27-13 |
| Biogen Idec's TECFIDERA? (Dimethyl Fumarate) Approved in US as a First-Line Oral Treatment for Multiple Sclerosis | 03-27-13 |
| New England IRB to Present ?IRB in Action? at 2013 MAGI Conference | 03-27-13 |
| SonoSite Launches Award-Winning AxoTrack Needle Guidance Technology | 03-27-13 |
| CardioReady Issues Comment on the FDA Proposal to Increase Regulation of Automated External Defibrillators (AEDs) | 03-27-13 |
| RetroSense Therapeutics Announces Exclusive Option to Intellectual Property Covering Vision Augmentation from Massachusetts General Hospital | 03-27-13 |
| Navidea Biopharmaceuticals Announces Enrollment of First Subject in Phase 2b Trial of NAV4694 in Subjects with Mild Cognitive Impairment (MCI) | 03-27-13 |
| POZEN Submits New Drug Application for PA32540/PA8140 | 03-27-13 |
| DIA Announces Class of 2013 Patient Fellowship Program Scholarship Recipients | 03-26-13 |
| FDA perspective published in the New England Journal of Medicine reinforces safety of Pradaxa® (dabigatran etexilate) | 03-26-13 |
| Acceleron Receives Two FDA Orphan Designations for ACE-536 | 03-26-13 |
| Aradigm Announces Fourth Quarter 2012 and Full Year Financial Results | 03-26-13 |
| U.S. Food and Drug Administration Approves Full Expansion of BioControl Medical's INOVATE-HF Study of the CardioFit® | 03-26-13 |
| Tenex Health Announces New FDA 510(k) Clearance for Its TX1 Tissue Removal System | 03-25-13 |
| Cook Pharmica Receives an Additional Commercial Approval from U.S. Food and Drug Administration | 03-25-13 |
| BioCryst Announces Initiation of a Phase 1 Clinical Trial of BCX4161 for the Treatment of Hereditary Angioedema | 03-25-13 |
| Cytori Provides Update in 510(k) Appeal Decision | 03-22-13 |
| ABC Laboratories Wins Industry Award for Quality | 03-22-13 |
| I risultati del trial RESPECT di St. Jude Medical vengono pubblicati nella rivista The New England Journal of Medicine | 03-22-13 |
| Genzyme Receives Positive CHMP Opinion in the European Union for Once-daily, Oral AUBAGIO® to Treat Relapsing-Remitting Multiple Sclerosis | 03-22-13 |
| FDA Approves GE Healthcare's AdreView? (Iobenguane I 123 Injection) for Cardiac Risk Evaluation in Heart Failure Patients | 03-22-13 |
| pSivida Reports Updates on ILUVIEN® for Planned Resubmission to FDA and European Launch | 03-22-13 |
| Effect of Genzyme's LEMTRADA? Maintained in Patients Beyond Two-Year Pivotal MS Studies | 03-21-13 |
| What If We Were No. 1?: The 2012 Colorado Health Report Card Answers the Question | 03-21-13 |
| Governor McDonnell Signs First in Nation Biosimilars Bill | 03-21-13 |
| Results of Lymphoseek® Phase 3 Clinical Trials in Breast Cancer Published in Annals of Surgical Oncology | 03-21-13 |
| Early versus Delayed Treatment with Laquinimod Demonstrated Significant Reduction in Risk of Disability Progression ? Results of Three-Year ALLEGRO Study in Relapsing-Remitting Multiple Sclerosis | 03-21-13 |
| MEDICREA Receives FDA Pediatric Clearance for PASS® LP Systems | 03-21-13 |
| FDA??????????????????????????TTP488??????????????? | 03-21-13 |
| Micron Technologies Announces Acquisition by Arlington Capital | 03-20-13 |
| Results of St. Jude Medical's RESPECT Trial Published in The New England Journal of Medicine | 03-20-13 |
| Samenvatting: Biogen Idec publiceert positieve resultaten fase 3-studie ADVANCE van PLEGRIDY (Peginterferon Beta-1a) | 03-20-13 |
| HiRes Optima? Sound Processing from Advanced Bionics Receives Worldwide Approval | 03-20-13 |
| FDA??TransTech Pharma???????????TTP488???????? | 03-20-13 |
| Proteo, Inc. /Proteo Biotech AG: FDA Grants Orphan Drug Designation to Elafin for Prevention of Inflammatory Complications of Transthoracic Esophagectomy | 03-20-13 |
| iCAD Announces FDA Clearance of Cervical Applicator for Xoft Electronic Brachytherapy System | 03-20-13 |
| Veristat's collaboration with Aegerion contributes to FDA approval of Juxtapid? | 03-20-13 |
| X-spine Announces FDA Clearance of New Implant System | 03-20-13 |
| ?Gummy Bear? Breast Implants Receive FDA Approval | 03-20-13 |
| Ethicon Receives 510(K) Clearance for ENSEAL® G2 Cordless | 03-20-13 |
| La Oficina de Patentes de Estados Unidos otorga patente sobre el régimen de administración de TECFIDERA TM (dimetilfumarato) | 03-20-13 |
| Samenvatting: US Patent Office verstrekt patent voor TECFIDERA (Dimethyl Fumarate) | 03-20-13 |
| Positive Year One Results from Biogen Idec Phase 3 ADVANCE Trial of PLEGRIDY? (Peginterferon Beta-1a) Presented at AAN Meeting | 03-20-13 |
| Des résultats positifs pour la première année des essais de phase III ADVANCE du PLEGRIDYMC (interféron bêta-1a pégylé) présentés à la réunion de l'AAN | 03-20-13 |
| Positive Ergebnisse nach einem Jahr der Phase-III-Studie ADVANCE zu PLEGRIDY? (Peginterferon Beta-1a) von Biogen Idec auf der AAN-Tagung vorgelegt | 03-20-13 |
| Risultati positivi per Biogen Idec per il primo anno della sperimentazione ADVANCE di fase 3 del PLEGRIDY? (peginterferone beta-1a) presentati al convegno dell'AAN | 03-20-13 |
| Presentados en la Reunión anual de la AAN los resultados positivos de un año del ensayo ADVANCE de Fase 3 de PLEGRIDY TM (peginterferon Beta-1a) de Biogen Idec | 03-20-13 |
| Diazepam Nasal Spray Demonstrates Comparable Bioavailability to Diazepam Rectal Gel in Pharmacokinetic Study | 03-20-13 |
| L'Office américain des brevets octroie un brevet portant sur le schéma posologique de TECFIDERA? (fumarate de diméthyle) | 03-20-13 |
| US-Patentamt erteilt Patent für TECFIDERA?-Dosierungsschema (Dimethylfumarat) | 03-20-13 |
| L'Ufficio Brevetti degli Stati Uniti concede il brevetto che descrive il regime posologico per TECFIDERA? (dimetilfumarato) | 03-20-13 |
| US Patent Office Grants Patent Claiming Dosing Regimen for TECFIDERA? (Dimethyl Fumarate) | 03-19-13 |
| Fenwal Secures New FDA Clearance for Device Designed to Help Increase Plasma Available for Transfusion | 03-19-13 |
| Samenvatting: FDA kent TransTech Pharma eerst Fast Track Designation toe voor TTP488 voor behandeling ziekte van Alzheimer | 03-19-13 |
| AcuFocus presenta ante la FDA la solicitud de autorización precomercialización para el implante KAMRA(TM) | 03-19-13 |
| AcuFocus apresenta PMA à FDA para aprovação do enxerto KAMRA(TM) | 03-19-13 |
| Samenvatting: AcuFocus levert PMA in bij FDA voor goedkeuring KAMRA-inlegwerk | 03-19-13 |
| Nuevos datos sobre TYSABRI confirman su notable eficacia en el tratamiento de pacientes con EM y demuestran la estabilidad de la condición de los anticuerpos contra el virus JC | 03-19-13 |
| EOS imaging Receives FDA Clearance for 3D Imaging Software featuring Post-operative Hip Implant Assessment | 03-19-13 |
| AcuFocus?FDA??KAMRA(TM)????PMA | 03-19-13 |
| Riassunto: AcuFocus presenta alla FDA richiesta di precommercializzazione per l'inserto KAMRA(TM) | 03-19-13 |
| AcuFocus présente une APMM à la FDA pour l?approbation de l?implant KAMRA(TM) | 03-19-13 |
| AcuFocus Submits PMA to FDA for Approval of the KAMRA(TM) Inlay | 03-19-13 |
| AcuFocus stellt Antrag auf PMA-Zulassung des KAMRA(TM)-Inlays bei der FDA | 03-19-13 |
| ?????????KAMRA(TM)???????????PMA?FDA??? | 03-19-13 |
| NPS Pharmaceuticals and Takeda Revise Agreements and NPS Re-Gains Full Worldwide Rights to Teduglutide and Recombinant Human Parathyroid Hormone 1-84 | 03-19-13 |
| FDA Grants TransTech Pharma Inc. Fast Track Designation for TTP488 for the Treatment of Alzheimer's Disease | 03-18-13 |
| FDA gewährt TransTech Pharma Inc. beschleunigte Zulassung für TTP488 zur Behandlung der Alzheimerkrankheit | 03-18-13 |
| La FDA accorde à TransTech Pharma Inc. la désignation Fast Track pour TTP488 dans le traitement de la maladie d'Alzheimer | 03-18-13 |
| La FDA Otorga a TransTech Pharma Inc. la Designación de Primera Línea para TTP488 para el Tratamiento de la Enfermedad de Alzheimer | 03-18-13 |
| Riassunto: L'Agenzia per gli Alimenti e i Medicinali statunitense (Food and Drug Administration, FDA) approva con procedura abbreviata TTP488 di TransTech Pharma Inc. per il trattamento del morbo di Alzheimer | 03-18-13 |
| A FDA concede à TransTech Pharma Inc. designação de via rápida ao TTP488 para o tratamento do mal de Alzheimer | 03-18-13 |
| Meridian Bioscience Announces illumigene® Group A Streptococcus and illumigene® Group B Streptococcus Tests Categorized ?Moderate Complexity? by FDA | 03-18-13 |
| Samenvatting: Covidien kondigt genomineerden voor raad van bestuur van Mallinckrodt Pharmaceutical | 03-18-13 |
| Seattle Genetics Submits Supplemental BLA to FDA for Retreatment and Extended Duration of Therapy with ADCETRIS® (Brentuximab Vedotin) in Relapsed Hodgkin Lymphoma and Systemic ALCL | 03-18-13 |
| Lantos Technologies Receives FDA Clearance for its 3D Ear Scanning System | 03-18-13 |
| De nouvelles données sur le TYSABRI réaffirment qu?il a une efficacité importante dans le traitement des personnes atteintes de SEP et démontrent la stabilité des titres d'anticorps contre le virus JC | 03-18-13 |
| New TYSABRI Data Reaffirm Substantial Efficacy in Treatment of People with MS and Demonstrate Stability of Anti-JCV Antibody Status | 03-18-13 |
| Neue Daten zu TYSABRI bestätigen beträchtliche Wirksamkeit bei der Behandlung von MS-Patienten und demonstrieren die Stabilität des JCV-Antikörper-Status | 03-18-13 |
| Nuovi dati sul TYSABRI ne confermano la notevole efficacia nel trattamento di pazienti affetti da SM e dimostrano la stabilità dello stato degli anticorpi anti-JCV | 03-18-13 |
| R-Tech Ueno: Start of the Patient Enrollment of a Phase 3 Clinical Study of Unoprostone (Development Code UF-021) Ophthalmic Solution for the Treatment of Retinitis Pigmentosa | 03-18-13 |
| Selon les données disponibles, le risque d'accident cardiovasculaire ou de décès chez les patients atteints du cancer de la prostate traités par Degarelix serait moindre comparé aux patients traités par les agonistes de la LH-RH | 03-17-13 |
| Los datos sugieren que existe un riesgo menor de episodios cardiovasculares o muerte en pacientes con cáncer de próstata tratados con degarelix, en comparación con aquellos tratados con agonistas de LHRH | 03-17-13 |
| Dados apontam um risco reduzido de ocorrências cardiovasculares ou morte em pacientes com câncer de próstata tratados com Degarelix comparado com pacientes tratados com agonistas de LHRH | 03-17-13 |
| Gegevens suggereren lager risico op cardiovasculaire gebeurtenissen of sterfgevallen bij patiënten met prostaatkanker behandeld met Degarelix vergeleken met LHRH-agonisten | 03-17-13 |
| Data Suggest Lower Risk of Cardiovascular Events or Deaths in Prostate Cancer Patients Treated with Degarelix Compared to LHRH Agonists | 03-17-13 |
| Aktuelle Studienergebnisse weisen auf niedrigeres Risiko für das Auftreten kardiovaskulärer Ereignisse oder Tod bei Prostatakrebspatienten, die mit Degarelix anstelle von LHRH-Agonisten behandelt werden | 03-17-13 |
| Cardiovascular Systems Completes PMA Submission of Orbital Atherectomy System for Coronary Artery Disease Treatment | 03-15-13 |
| AMAG Pharmaceuticals Announces Positive Preliminary Results from an Extension Study Evaluating the Safety and Efficacy of Repeat Dosing with Ferumoxytol in Patients with Persistent or Recurring Iron Deficiency Anemia, Regardless of the Underlying Cause | 03-15-13 |
| Pathwork Diagnostics Collaborating with Kindstar Global to Provide Tissue of Origin Test in China | 03-14-13 |
| GenSpera's G-202 Granted U.S. Orphan Drug Designation for Treatment of Hepatocellular Carcinoma | 03-14-13 |
| BioClinica and CoreLab Partners Are One | 03-14-13 |
| Brain & Behavior Research Foundation Awards Nearly $4 Million in NARSAD Grants for Cutting-Edge Research on Mental Illness | 03-13-13 |
| Early Susan G. Komen for the Cure® Research Funding Leads to New Diagnostic Tool for Cancer's Spread | 03-13-13 |
| Navidea Biopharmaceuticals to Hold Conference Call to Discuss Lymphoseek FDA Approval | 03-13-13 |
| Neos Therapeutics, Inc. Announces FDA Accepts NDA Filing for Extended Release Amphetamine Polistirex for the Once-Daily Treatment of ADHD | 03-13-13 |
| FDA Approves Navidea's Lymphoseek® (technetium Tc 99m tilmanocept) Injection for Use in Lymphatic Mapping | 03-13-13 |
| Theorem Clinical Research Expands Partnership with Medidata Solutions | 03-13-13 |
| RTI Biologics® Receives 510(k) Clearance for Porcine Dermis Implant | 03-13-13 |
| Antares Pharma Reports Fourth Quarter and Full Year 2012 Operating and Financial Results | 03-13-13 |
| Genzyme's Multiple Sclerosis Franchise Featured at AAN | 03-13-13 |
| Samenvatting: Biogen Idec vraagt toestemming aan FDA voor 1e Factor VIII therapie gericht op hemofilie A | 03-12-13 |
| Biogen Idec richiede alla FDA l'approvazione per la prima terapia a lungo termine per l'emofilia A basata sul fattore VIII | 03-12-13 |
| Biogen Idec presenta solicitud ante la FDA para el primer tratamiento de factor VIII de acción prolongada contra la hemofilia A | 03-12-13 |
| Biogen Idec reicht Zulassungsantrag für erste langwirkende Faktor-VIII-Therapie zur Behandlung von Hämophilie A bei FDA ein | 03-12-13 |
| Sundance Diagnostics Announces it will Target Risk of Suicide and Risk of Violence in Development of its Genetic Tests to Curb Prescription Drug Side Effects | 03-12-13 |
| Biogen Idec Submits Application to FDA for First Long-Lasting Factor VIII Therapy for Hemophilia A | 03-12-13 |
| Biogen Idec soumet une demande à la FDA pour le premier traitement à facteur VIII à action prolongée contre l'hémophilie A | 03-12-13 |
| Samenvatting: Gore lanceert GORE EXCLUDER AAA Endoprosthesis contralaterale beencomponenten in VS en Europa | 03-11-13 |
| Resumen: Gore lanza componentes de rama contralateral de endoprótesis de perfil reducido para GORE® EXCLUDER® AAA en Estados Unidos y Europa | 03-11-13 |
| AtriCure Appoints Robert S. White to its Board of Directors | 03-11-13 |
| CytRx Reports 2012 Financial Results | 03-11-13 |
| St. Jude Medical Announces Launch of 3-D Vessel Reconstruction Technology in Japan | 03-11-13 |
| OptosOCT/SLO ? Retinal Structure and Functional Testing in One Device | 03-11-13 |
| Gore Launches Lower Profile GORE® EXCLUDER® AAA Endoprosthesis Contralateral Leg Components in US and Europe | 03-11-13 |
| Riassunto: Gore lancia delle componenti iliache (gambe controlaterali) a profilo ridotto per l'endoprotesi AAA GORE® EXCLUDER® negli Stati Uniti e in Europa | 03-11-13 |
| Gore lanciert-Niederprofil-Gegenseite-Beinkomponenten für GORE® EXCLUDER® AAA Endoprothese in den USA und Europa | 03-11-13 |
| Gore lance des composants de branche contralatérale d'endoprothèse à profil réduit GORE® EXCLUDER ® AAAaux États-Unis et en Europe | 03-11-13 |
| A Statement from the International Academy of Compounding Pharmacists | 03-11-13 |
| RegeneRx Receives Notice of Allowance for 2nd U.S. Heart Patent | 03-08-13 |
| St. Jude Medical Announces First Implant in Pivotal Phase of Clinical Trial Evaluating AMPLATZER Cardiac Plug for the Prevention of Stroke in Patients with Atrial Fibrillation | 03-08-13 |
| Samenvatting: Biogen Idec presenteert nieuwe data neurologisch portfolio op AAN-jaarvergadering | 03-08-13 |
| Biogen Idec stellt neue Ergebnisse zu vielfältigem neurologischen Portfolio auf der 65. AAN-Jahrestagung vor | 03-08-13 |
| Biovest Files Recapitalization Plan to Strengthen Balance Sheet and Advance Commercialization Strategy for BiovaxID? Cancer Vaccine | 03-07-13 |
| ADMA Biologics Commences Pivotal Phase III Clinical Study of RI-002 in PIDD Patients | 03-07-13 |
| Biogen Idec presenta nuevos datos sobre sus diversas carteras neurológicas durante el 65º Congreso Anual de la AAN | 03-07-13 |
| Biogen Idec presenterà i nuovi dati relativi al suo portafoglio di prodotti neurologici durante il 65° Meeting annuale dell'Accademia americana di neurologia | 03-07-13 |
| Hi-Tech Pharmacal Reports Sales of $64.3 Million and EPS of $0.43 for the Third Quarter Ended January 31, 2013 | 03-07-13 |
| Otsuka Advancing Rapidly in Central Nervous System Disorders; Expanding Existing Collaboration with Lundbeck | 03-07-13 |
| ??????????????????????????????????? | 03-07-13 |
| Biogen Idec présente de nouvelles données sur ses divers portefeuilles neurologiques lors de la 65e conférence annuelle de l'AAN | 03-07-13 |
| Navidea Announces Fourth Quarter and Full-Year 2012 Results | 03-06-13 |
| Biogen Idec to Present New Data on Diverse Neurological Portfolio at 65th AAN Annual Meeting | 03-06-13 |
| New Data Shows Reliability and Efficacy Fuel Trust and Preference for OTC Options | 03-06-13 |
| NanoString Technologies Presents Positive Results from Multisite Analytical Validation Study of Prosigna? Breast Cancer Prognostic Gene Signature Assay | 03-06-13 |
| Lantheus Medical Imaging Announces Appointment of Cesare Orlandi, M.D., as New Chief Medical Officer | 03-06-13 |
| AMAG Pharmaceuticals Announces FDA Acceptance of Supplemental New Drug Application for Feraheme Label Expansion to Include Iron Deficiency Anemia Patients Who Cannot Take Oral Iron | 03-06-13 |
| Vital 5 Receives Clearance from the FDA for a First-To-Market, Dual Function Catheter System that Provides Simultaneous Anesthetic Infusion and Wound Drainage | 03-06-13 |
| CircuLite® Receives Conditional IDE Approval for SYNERGY® Circulatory Support System Feasibility Trial | 03-05-13 |
| United States Patent & Trademark Office Grants Pfizer Reissue Patent For Celebrex® (celecoxib capsules) | 03-05-13 |
| NPS Pharmaceuticals to Present at Barclays Capital Global Healthcare Conference | 03-05-13 |
| AHF Demands FDA Reversal on Use of Gilead's HIV Prevention Pill for Women | 03-05-13 |
| OPKO Health Completes Acquisition of Two Phase 3 Products | 03-04-13 |
| Impax Provides an Update on FDA Inspection of Hayward Facility | 03-04-13 |
| Navidea Biopharmaceuticals to Announce Fourth-Quarter and Full-Year 2012 Financial Results on Wednesday, March 6, 2013 | 03-04-13 |
| Genzyme's Head of Rare Diseases Honored by the Genetic Disease Foundation | 03-04-13 |
| Iroko Pharmaceuticals Announces Acceptance for NDA Filing of Lower Dose Submicron Diclofenac for the Treatment of Mild to Moderate Acute Pain in Adults | 03-04-13 |
| FDA Accepts Biogen Idec's Biologics License Application for First Long-Lasting Factor IX Therapy for Hemophilia B | 03-04-13 |
| Research and Markets: Alexion Pharmaceuticals, Inc.: Focus on Ultra-rare Diseases as a Revenue and Profit Driver | 03-01-13 |
| A.P. Pharma Announces Fourth Quarter and Full Year 2012 Financial Results and Highlights Recent Corporate Progress | 03-01-13 |
| ???????????????????1???????????ABILIFY MAINTENA???????? ????? ??????????????FDA???? | 03-01-13 |
| FDA Approves Once-Monthly ABILIFY MAINTENA? (aripiprazole) for Extended-Release Injectable Suspension for the Treatment of Schizophrenia | 02-28-13 |
| AtriCure Reports Fourth Quarter and Full Year 2012 Financial Results | 02-28-13 |
| FDA Grants QIDP and Fast Track Designations for Cubist's Late-Stage Antibiotic Candidates | 02-28-13 |
| BIO Praises U.S. Senate for Passing the Pandemic and All-Hazards Preparedness Reauthorization Act | 02-28-13 |
| Navidea Biopharmaceuticals to Present at the Cowen & Company 33rd Annual Health Care Conference | 02-28-13 |
| Samenvatting: Alexion sluit zich aan bij EURORDIS, NORD en patiëntenorganisaties voor viering Rare Disease Day 2013 | 02-28-13 |
| Resumen: Alexion se une a EURORDIS, NORD y organizaciones de pacientes internacionales para celebrar el día mundial de las enfermedades raras 2013 | 02-28-13 |
| A.P. Pharma Appoints Jesse Hollingsworth as Vice President of Sales | 02-28-13 |
| Camargo and XenoTech Present Webinar Using 505(b)(2) to Accelerate Drug Approval | 02-28-13 |
| Advaxis to Provide 2013 Business Outlook on March 6, 2013 | 02-28-13 |
| KLOX Technologies to Meet with Leaders in Acne During the American Academy of Dermatology Annual Meeting in Miami | 02-28-13 |
| InVivo Therapeutics Submits Updated IDE to FDA to Begin Spinal Cord Injury Human Study | 02-28-13 |
| Intralytix Wins Regulatory Approval For Phage-Based Food Safety Product Effective Against Salmonella | 02-28-13 |
| Riassunto: Alexion celebra con EURORDIS, NORD e le organizzazioni di pazienti di tutto il mondo la Giornata delle malattie rare 2013 | 02-28-13 |
| Alexion se joint à EURORDIS, NORD et les organisations de patients dans le monde pour célébrer la Journée des maladies rares 2013 | 02-28-13 |
| Alexion begeht den Tag der seltenen Krankheiten 2013 gemeinsam mit EURORDIS und Patientenorganisationen weltweit | 02-28-13 |
| Alexion Joins EURORDIS, NORD and Patient Organizations Worldwide in Celebrating Rare Disease Day 2013 | 02-28-13 |
| Alexion ställer sig bakom EURORDIS, NORD och patientorganisationer runt om i världen för att uppmärksamma Sällsynta dagen 2013 | 02-28-13 |
| St. Jude Medical to Present at the Barclays Global Healthcare Conference | 02-27-13 |
| MiraMed Counts Down to Operation Sequestration | 02-27-13 |
| Ceptaris Resubmits New Drug Application (NDA) to FDA for Proprietary Gel Formulation of Mechlorethamine Hydrochloride | 02-27-13 |
| UMF Corporation Names David A. Roberson to New Post | 02-27-13 |
| Resumen: Irvine Scientific anuncia que su fábrica de Tokio ha recibido la certificación ISO 9001:2008 | 02-27-13 |
| Samenvatting: Irvine Scientific: Tokio faciliteit heeft ISO 9001:2008 certificering ontvangen | 02-27-13 |
| Sunovion Announces FDA Acceptance for Review of New Drug Application Resubmission for STEDESA® (eslicarbazepine acetate) as a Once-Daily Adjunctive Therapy for Partial-onset Seizures in Adults with Epilepsy | 02-27-13 |
| Antares Pharma Announces FDA Acceptance of New Drug Application for OTREXUP? | 02-27-13 |
| ZERTIFIZIERUNG des Betriebs von Irvine Scientific in Tokio nach ISO 9001:2008 | 02-27-13 |
| Irvine Scientific annonce que son installation de Tokyo a obtenu la CERTIFICATION ISO 9001:2008 | 02-27-13 |
| Riassunto: Irvine Scientific annuncia che il proprio stabilimento di Tokyo ha ottenuto la CERTIFICAZIONE ISO 9001:2008 | 02-27-13 |
| Irvine Scientific Announces Its Tokyo Facility Has Received ISO 9001:2008 CERTIFICATION | 02-27-13 |
| Genzyme Receives Company Award from European Organisation for Rare Diseases (EURORDIS) | 02-27-13 |
| Hi-Tech Pharmacal to Present at the 2013 RBC Capital Markets? Healthcare Conference | 02-26-13 |
| American Association of Clinical Endocrinologists, American Diabetes Association Issue Joint Response to Published JAMA Article | 02-26-13 |
| Crystal Pharmatech and Particle Sciences Form a US-China Pharmaceutical CRO Partnership | 02-26-13 |
| STENTYS to Present Final Results From 1,000 Heart Attack Patient Study at ACC.13 | 02-26-13 |
| ClinStar to Host Live Webinar Evaluating Clinical Trial Quality in Russia and Ukraine Compared to the West and Other Emerging Markets | 02-26-13 |
| Furiex Pharmaceuticals to Present at Cowen & Company 33rd Annual Healthcare Conference | 02-26-13 |
| Baxter Submits Application for FDA Approval of FEIBA NF for Prophylactic Use in Hemophilia A and B Patients with Inhibitors | 02-26-13 |
| FDA Advisory Panel Recommends Approval of the NeuroPace RNS® System for Medically Refractory Epilepsy | 02-26-13 |
| PURE Bioscience Reports 2013 Second Fiscal Quarter Financial Results | 02-26-13 |
| GPMG's Quality System Product Speeds ISO 13485 Certification for Manufacturers of Medical Devices | 02-26-13 |
| NanoViricides, Inc. Announces that Renovation for its cGMP Clinical Drug Facility has Begun; also Addresses Shareholder Concern - Knows No Reason for the Price Drop Yesterday | 02-26-13 |
| Furiex Receives Qualified Infectious Disease Product and Fast Track Designations from the U.S. Food and Drug Administration for Avarofloxacin (JNJ-Q2) | 02-25-13 |
| Impax Laboratories Reports Fourth Quarter and Full Year 2012 Results | 02-25-13 |
| CSI Presents Three-Year Orbit I Coronary Data at CRT 2013 | 02-25-13 |
| FDA Approves First Single-Lead ICD with Atrial Sensing | 02-25-13 |
| ReVision Optics Receives FDA Approval to Complete Enrollment in Its Phase III Clinical Trial with the Raindrop Near Vision Inlay for Improving Near Vision in Patients with Presbyopia | 02-25-13 |
| Atossa Genetics Receives Warning Letter From the Food and Drug Administration | 02-25-13 |
| PLC Systems Raises $4,040,000 in Equity Financing | 02-25-13 |
| Ocular Therapeutix Completes PMA Submission for ReSure® Sealant | 02-25-13 |
| Amneal Pharmaceuticals Receives FDA Approval for Generic Suboxone® | 02-25-13 |
| Affymax and Takeda Announce a Nationwide Voluntary Recall of All Lots of OMONTYS® (peginesatide) Injection | 02-24-13 |
| ImmunoGen, Inc. Announces FDA Approval of Kadcyla (Ado-Trastuzumab Emtansine; Also Known as T-DM1) | 02-22-13 |
| FDA Approves Genentech's Kadcyla (Ado-Trastuzumab Emtansine), the First Antibody-Drug Conjugate for Treating HER2-Positive Metastatic Breast Cancer | 02-22-13 |
| Merck to Present New Data Analyses of its Investigational Ragweed Pollen and Grass Pollen Allergy Immunotherapy Tablets | 02-22-13 |
| NPS Pharmaceuticals Reports 2012 Financial Results and 2013 Guidance | 02-21-13 |
| Oceana Study Uncovers Widespread Seafood Fraud Nationwide | 02-21-13 |
| SOV????????????????14-17???????????????????????????????????????????????????? | 02-21-13 |
| FDA Approves Natrelle® 410 Highly Cohesive Anatomically Shaped Silicone-Filled Breast Implants | 02-20-13 |
| American Association of Clinical Endocrinologists Publishes Lipodystrophy Consensus Statement | 02-20-13 |
| ISR Report Shows Late Phase Study Conduct, Outsourcing Continues to Rise | 02-20-13 |
| Samenvatting: SOV Therapeutics krijgt US Orphan Drug Designation voor gebruik 'oral testosterone undecanoate' voor behandeling groeiachterstand bij tienerjongens | 02-20-13 |
| Resumen: SOV Therapeutics obtiene la designación de medicamento huérfano en Estados Unidos para el uso del undecanoato de testosterona oral en el tratamiento del retraso constitucional... | 02-20-13 |
| Puma Biotechnology Announces Agreement with FDA on Special Protocol Assessment for Phase III Trial of PB272 (Neratinib) in HER2-Positive Metastatic Breast Cancer Patients | 02-20-13 |
| SOV Therapeutics erhält US-Zulassung als Orphan-Arzneimittel für Testosteron Undecanoat zur oralen Behandlung von körperlich bedingten Wachstums- und Pubertätsverzögerungen bei männlichen Jugendlichen (im Alter zwischen 14 und 17 Jahren) | 02-20-13 |
| SOV Therapeutics obtient la désignation de médicament orphelin aux États-Unis pour l'utilisation de l'undécanoate de testostérone oral dans le traitement du retard constitutionnel de croissance et de puberté des garçons adolescents... | 02-20-13 |
| Riassunto: SOV Therapeutics ottiene la designazione di farmaco orfano negli Stati Uniti per l'uso del testosterone undecanoato in formulazione orale per il trattamento del ritardo costituzionale di crescita e pubertà in adolescenti di sesso... | 02-20-13 |
| SOV Therapeutics Receives US Orphan Drug Designation for the Use of Oral Testosterone Undecanoate in the Treatment of Constitutional Delay in Growth and Puberty in Adolescent Boys (14-17 Years of Age) | 02-20-13 |
| Inspiration Biopharmaceuticals and Ipsen Announce Closing of the IB1001 Sale to Cangene Corporation | 02-20-13 |
| Jonathan S. Helfgott, FDA Compliance Officer for Center for Drug Evaluation & Research (CDER), to Address PHT Corporation U.S. PRO & eCOA Congress | 02-19-13 |
| Navidea Biopharmaceuticals to Present at the Citi 2013 Global Healthcare Conference | 02-19-13 |
| Dallen Medical Receives FDA Clearance for New Compressyn? Staple for Rigid Small Bone Fixation | 02-19-13 |
| Advaxis Announces Phase 1/2 Trial of ADXS-HPV in Anal Cancer Conducted by Brown University Oncology Group | 02-19-13 |
| AtriCure to Announce Fourth Quarter and Full Year 2012 Financial Results | 02-18-13 |
| ???????????POMALYST®????????????????????????? | 02-18-13 |
| Celgene????REVLIMID®??????? | 02-18-13 |
| Exact Sciences Submits Second Module of Premarket Approval Application to FDA | 02-18-13 |
| Genzyme Announces Positive New Data from Two Phase 3 Studies for Oral Eliglustat Tartrate for Gaucher Disease | 02-15-13 |
| Samenvatting: Second Sight Medical Products krijgt FDA goedkeuring voor Argus II-systeem | 02-15-13 |
| Resumen: Second Sight Medical Products recibe aprobación de la FDA para el sistema Argus II | 02-15-13 |
| Cure Duchenne Hosts Accelerated Access Webinar with the FDA | 02-14-13 |
| BioAlliance Pharma announces the forthcoming extension of its phase II clinical trial with Validive® in the United States | 02-14-13 |
| BioAlliance Pharma annonce l?extension prochaine aux Etats-Unis de son essai clinique de phase II avec Validive® | 02-14-13 |
| Riassunto: Second Sight Medical Products ottiene l'approvazione dell'ente statunitense preposto al controllo dei farmaci e degli alimenti (Food and Drug Administration, FDA) per il sistema Argus II | 02-14-13 |
| Second Sight Medical Products reçoit l'approbation de l'Agence fédérale américaine des produits alimentaires et médicamenteux (FDA) pour le système Argus II | 02-14-13 |
| Second Sight Medical Products erhält FDA-Zulassung für Argus II-System | 02-14-13 |
| Second Sight Medical Products Receives FDA Approval for Argus II System | 02-14-13 |
| Teva Announces FDA Approval of Generic Adderall XR® | 02-14-13 |
| Cerus to Release Fourth Quarter and Year-End 2012 Results on February 28, 2013 | 02-14-13 |
| Santarus Announces Commercial Launch of UCERIS (budesonide) Extended Release Tablets | 02-14-13 |
| ????????POMALYST®??????????????????????????????? | 02-14-13 |
| NORD, BioNJ and Patient Advocacy Groups to Collaborate on Rare Disease Day Event at New Jersey State House | 02-13-13 |
| Loma Vista Medical Reports That It is Ramping up Sales in U.S. and Europe of its FDA-Cleared and CE-Marked TRUE Dilatation? Balloon Valvuloplasty Catheter Specifically Designed to Reduce ?Rapid Pacing? Time and Prevent Balloon Failure | 02-13-13 |
| World's First FDA Cleared ALK Automated Gene Scanner for Lung Cancer Therapy-Selection Available from ASI | 02-13-13 |
| ?Coming to America? Webinar Looks at Options for Foreign Drug and Device Companies | 02-13-13 |
| Acorda Therapeutics Reports Fourth Quarter and Full Year 2012 Financial Results | 02-13-13 |
| McLaren Cancer Institute Names New Leader | 02-12-13 |
| Freedom Meditech Receives FDA 510(k) Clearance for ClearPath DS-120? | 02-12-13 |
| Paragonix Technologies, Inc., Announces Clearance of a 510(k) Pre-Marketing Notification Application with the US Food and Drug Administration for the Paragonix Sherpa? Cardiac Transport System | 02-12-13 |
| ??????????????????????????? | 02-12-13 |
| R-Tech Ueno: Lawsuit Claiming Infringement of AMITIZA® Capsules Patents | 02-12-13 |
| Celgene fornece atualização regulatória do REVLIMID® | 02-11-13 |
| AB SCIEX Responds to Milk Contamination Concerns with New Method to Detect Dicyandiamide | 02-11-13 |
| Celgene proporciona actualización reglamentaria de REVLIMID® | 02-11-13 |
| La Fundación Internacional del Mieloma afirma que la innovación médica ayuda a los pacientes a vivir más tiempo y mejor | 02-11-13 |
| Samenvatting: U.S. Food & Drug Administration keurt POMALYST (pomalidomide) goed voor behandeling patiënten met ziekte van Kahler | 02-11-13 |
| Lantheus Medical Imaging Announces FDA Approval of Jubilant HollisterStier as a New Manufacturing Site for DEFINITY® | 02-11-13 |
| Riassunto: Celgene fornisce aggiornamento normativo sul REVLIMID® | 02-11-13 |
| Celgene fournit une mise à jour réglementaire sur le REVLIMID® | 02-11-13 |
| Celgene veröffentlicht aktuelle Mitteilung zur Zulassung von REVLIMID® | 02-11-13 |
| Celgene Provides REVLIMID® Regulatory Update | 02-11-13 |
| La Food and Drug Administration des États-Unis approuve POMALYST® (pomalidomide) pour le traitement des patients atteints du myélome multiple myélome multiple récurrent/réfractaire | 02-10-13 |
| A Administração de Alimentos e Medicamentos dos EUA aprova o uso do medicamento POMALYST® (pomalidomida) no tratamento de pacientes com mieloma múltiplo reincidente e refratário | 02-10-13 |
| La Administración de Alimentos y Medicamentos de EE.UU. aprueba POMALYST® (pomalidomida) para el tratamiento de pacientes con mieloma múltiple reincidente y refractario | 02-09-13 |
| Riassunto: L'agenzia per gli alimenti e medicinali degli Stati Uniti dà la sua approvazione a POMALYST® per la cura di pazienti affetti da mieloma multiplo e in particolare in casi di refrattarietà o recidiva | 02-09-13 |
| US-amerikanische FDA erteilt Zulassung für POMALYST® (Pomalidomid) zur Behandlung von Patienten mit rezidiviertem und refraktärem multiplem Myelom | 02-09-13 |
| La International Myeloma Foundation afferma che l'innovazione medica sta aiutando i pazienti a vivere più a lungo e con una migliore qualità della vita | 02-08-13 |
| De International Myeloma Foundation zegt dat medische innovatie patiënten helpt om een langer, beter leven te leven | 02-08-13 |
| La Fondation internationale du myélome affirme que l?innovation médicale aide les patients à vivre mieux et plus longtemps | 02-08-13 |
| Laut International Myeloma Foundation verhilft medizinische Innovation Patienten zu einem längeren und besseren Leben | 02-08-13 |
| The International Myeloma Foundation Says Medical Innovation Is Helping Patients Live Longer, Better Lives | 02-08-13 |
| Multiple Myeloma Research Foundation (MMRF) Celebrates the FDA Accelerated Approval of Pomalyst® (pomalidomide) for the Treatment of Relapsed and Refractory Multiple Myeloma | 02-08-13 |
| U.S. Food and Drug Administration Approves POMALYST® (pomalidomide) for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma | 02-08-13 |
| New Phase 3 Data Reinforce Long-Lasting Protection from Bleeding for Patients with Hemophilia A and B | 02-08-13 |
| Sucampo Files Patent Infringement Lawsuit Against Anchen Pharmaceuticals and Par Pharmaceuticals | 02-08-13 |
| Parenting Health News: Importance Of Following FDA Warnings On SimplyThick Thickening Agent Highlighted in New York Times Report | 02-07-13 |
| Fully Automatic AED Plus from ZOLL Granted 510(k) Clearance by U.S. Food and Drug Administration | 02-07-13 |
| CorMedix Granted Extension of NYSE MKT Listing | 02-07-13 |
| Navidea Biopharmaceuticals Announces the Presentation of Lymphoseek® Data at Upcoming Scientific Meetings | 02-07-13 |
| RTI Biologics Announces 2012 Fourth Quarter, Full Year Results, 2013 Financial Guidance | 02-07-13 |
| Affymetrix and DNA Link Sign Partnership for Forensic Test Development for Human Identification | 02-07-13 |
| LeafyGreens.com ? A New Comprehensive Food Safety Resource ? Is Launched as FDA Proposes New Food Safety Rules | 02-06-13 |
| Navidea Biopharmaceuticals to Present at the 15th Annual BIO CEO & Investor Conference | 02-06-13 |
| Smiths Medical Receives FDA Clearance for CADD-Solis VIP Ambulatory Infusion System | 02-06-13 |
| FluGen's Universal Flu Vaccine REDEE FLU? Showcased at World Health Organization Influenza Meeting | 02-06-13 |
| The Institute for Systems Biology and AB SCIEX Partner to Help Make Medical Care More Predictive and Personalized | 02-06-13 |
| BioClinica Announces Fourth Quarter and Full Year 2012 Financial Results | 02-06-13 |
| SurModics to Webcast Annual Meeting on February 11 | 02-06-13 |
| NPS Pharmaceuticals to Present at Upcoming Conferences | 02-05-13 |
| Navidea Biopharmaceuticals Participates in Symposium Focused on Sentinel Lymph Node Biopsy at the International Symposium on Metastasis in Head and Neck Cancer | 02-05-13 |
| Taro Provides Third Quarter and Fiscal Year to Date Results | 02-04-13 |
| WAISMANN METHOD® Director Urges Physicians to Curb Hydrocodone Prescriptions | 02-04-13 |
| Medical Device Using Evonik's VESTAKEEP® PEEK Receives First FDA Spinal 510(K) Approval | 02-04-13 |
| Navidea to Collaborate with Maimonides Medical Center on Clinical Trial Utilizing Lymphoseek® for Lymphatic Mapping in Colorectal Cancer | 02-04-13 |
| Ethicon Receives 510(k) Clearance for ENSEAL® G2 Articulating | 02-04-13 |
| IGI Laboratories, Inc. Acquires Econazole Nitrate Cream | 02-04-13 |
| NanoViricides Raises $6M from Equity Investors - Reports Having Sufficient Funds for the Initial Human Clinical Trials of its Broad-spectrum anti-Influenza Drug | 02-04-13 |
| US FDA Extends License of the GVK BIO Biomarker Database | 02-04-13 |
| First U.S. Case Performed with Endosense's TactiCath® Quartz Contact-Force Sensing Ablation Catheter | 02-01-13 |
| AtriCure to Present at the Leerink Swann 2013 Global Healthcare Conference | 01-31-13 |
| Resonance Health's FerriScan® R2-MRI Receives FDA Marketing Authorization as the First Imaging Companion Diagnostic Device for Exjade® in Patients with Non-Transfusion-Dependent Thalassemia (NTDT) | 01-31-13 |
| Santen Pharmaceutical Co., Ltd. and Clearside Biomedical, Inc. Enter into Financing and Research Collaboration Agreements for Posterior Ocular Disease | 01-31-13 |
| Daiichi Sankyo and ArQule Enroll First Hepatocellular Carcinoma Patient into Global Phase 3 Trial for Tivantinib | 01-31-13 |
| PaxVax Announces Positive Results for Oral Ad4 Vaccine Technology | 01-31-13 |
| MP?????????HTLV???????????????????BLA??FDA??? | 01-31-13 |
| SurModics Reports First Quarter Fiscal 2013 Results | 01-30-13 |
| AOAC Research Institute Extends PTM Approval to 3M Molecular Detection Assay Listeria for Foods | 01-30-13 |
| Octaplas® obtient l'approbation de la FDA pour l'expansion des thérapies transfusionnelles Octapharma aux États-Unis | 01-30-13 |
| Genzyme and Isis Announce FDA Approval of KYNAMRO? (mipomersen sodium) Injection for the Treatment of Homozygous Familial Hypercholesterolemia | 01-29-13 |
| FDA Advisory Committee Recommends Approval for Boehringer Ingelheim's Olodaterol* for Maintenance Treatment of COPD | 01-29-13 |
| Furiex Pharmaceuticals Announces Fourth Quarter and Full Year 2012 Earnings Release and Conference Call | 01-29-13 |
